Fig. 3: Safety profile of nivolumab in combination with carboplatin and etoposide. | Nature Communications

Fig. 3: Safety profile of nivolumab in combination with carboplatin and etoposide.

From: Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)

Fig. 3

A Treatment-related adverse events encountered in >5% of patients. The graph represents the worst grade per patient. The percentage of patients experiencing an event is depicted (n = 37). B Distribution of toxicities by study phase (induction versus maintenance phase) from first dose of study treatment until last follow-up (n = 37 for concomitant phase and n = 24 for maintenance phase). Source data are provided as a Source Data file.

Back to article page